Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 7551 - 7575 of 8033 in total
MLN-977 is a small molecule compound that inhibits the production of leukotrienes, especially 5-lipoxygenase. It is developed by PharmaEngine to treat asthma and chronic obstructive pulmonary disease.
Investigational
Matched Description: … MLN-977 is a small molecule compound that inhibits the production of leukotrienes, especially 5-lipoxygenase …
TNX-901 is a therapeutic monoclonal antibodies designed to address significant unmet medical needs in the areas of asthma, allergy, inflammation and other diseases affecting the human immune system.
Investigational
Matched Description: … therapeutic monoclonal antibodies designed to address significant unmet medical needs in the areas of
BIIB015 is a humanized, IgG1 [immunoglobulin G 1], DM4-Conjugated, anti-cripto, monoclonal antibody. It has been investigated for the treatment of subjects with relapsed or refractory solid tumours.
Investigational
Matched Description: … It has been investigated for the treatment of subjects with relapsed or refractory solid tumours. …
Etofibrate is a fibrate produced by the combination of clofibrate ester linked to niacin. These components separate in the body slowly allowing for pharmacokinetics similar to controlled-release formulations.
Experimental
Matched Description: … Etofibrate is a fibrate produced by the combination of clofibrate ester linked to niacin. …
Incyclinide has been used in trials studying the treatment of HIV Infection, AIDS-related Kaposi Sarcoma, Brain and Central Nervous System Tumors, and Unspecified Adult Solid Tumor, Protocol Specific.
Investigational
Matched Description: … Incyclinide has been used in trials studying the treatment of HIV Infection, AIDS-related Kaposi Sarcoma …
Tesidolumab has been used in trials studying the treatment of Geographic Atrophy, Non-infectious Panuveitis, Exudative Macular Degeneration, Non-infectious Posterior Uveitis, and Age-related Macular Degeneration, among others.
Investigational
Matched Description: … Tesidolumab has been used in trials studying the treatment of Geographic Atrophy, Non-infectious Panuveitis …
Dusigitumab has been used in trials studying the treatment of Cancer, Advanced Solid Malignancies, Unresectable or Metastatic Hepatocellular Carcinoma (HCC), and Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer.
Investigational
Matched Description: … Dusigitumab has been used in trials studying the treatment of Cancer, Advanced Solid Malignancies, Unresectable …
Balipodect is under investigation in clinical trial NCT01892189 (Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults).
Investigational
Matched Description: … Balipodect is under investigation in clinical trial NCT01892189 (Effects of TAK-063 on Preventing Ketamine-Induced …
AZD-1656 is under investigation in clinical trial NCT00747175 (A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes).
Investigational
Matched Description: … NCT00747175 (A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of
Pamrevlumab is under investigation in clinical trial NCT00913393 (Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy).
Investigational
Matched Description: … Pamrevlumab is under investigation in clinical trial NCT00913393 (Study of FibroGen (FG)-3019 in Subjects …
Revaprazan is under investigation in clinical trial NCT01750437 (Phase 2 Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH1885L in Patients With Non-erosive Reflux Disease(nerd)).
Investigational
Matched Description: … clinical trial NCT01750437 (Phase 2 Clinical Trial to Investigate the Safety, Tolerability and Efficacy of
Non-methylated, competitive, and irreversible inhibitor of caspase 1, as well as other caspases,1 which can be used directly with purified enzymes. It does not require an esterase to hydrolyze the O-methyl ester like the cell-permeable form, Z-Val-Ala-Asp(O-Me) fluoromethyl ketone.
Experimental
Matched Description: … Non-methylated, competitive, and irreversible inhibitor of caspase 1, as well as other caspases,1 which …
Natural killer (NK) cells can be incubated with ‘feeder cells’ expressing certain cytokines prior to maturation to enhance their activity. In particular, incubation with IL-15 allows NK cells to lyse a broad range of fresh and cultured tumor targets that the cell is not normally sensitive to.
Investigational
Matched Description: … In particular, incubation with IL-15 allows NK cells to lyse a broad range of fresh and cultured tumor …
ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile.
Investigational
Matched Description: … ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive …
Luveltamab tazevibulin, formerly known as STRO-002, is novel homogeneous folate receptor alpha (FolRα) targeting antibody-drug conjugate. It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer).
Investigational
Matched Description: … [A257414] It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate …
An organic compound used often as a reagent in organic synthesis, as a flavoring agent, and in tanning. It has been demonstrated as an intermediate in the metabolism of acetone and its derivatives in isolated cell preparations, in various culture media, and in vivo in certain animals. [PubChem]
Experimental
Matched Description: … It has been demonstrated as an intermediate in the metabolism of acetone and its derivatives in isolated …
L-cysteic acid is a beta-sulfoalanine. It is an amino acid with a C-terminal sulfonic acid group which has been isolated from human hair oxidized with permanganate. It occurs normally in the outer part of the sheep's fleece, where the wool is exposed to light and weather.
Experimental
Matched Description: … It occurs normally in the outer part of the sheep's fleece, where the wool is exposed to light and weather …
A humanized monoclonal antibody directed against sphingosine 1-phosphate (S1P) with potential antiangiogenic and antineoplastic activities. Upon administration, sonepcizumab binds S1P, which may result in the inhibition of tumor angiogenesis. S1P is the extracellular ligand for the G protein-coupled lysophospholipid receptor EDG-1 (endothelial differentiation gene-1).
Investigational
Matched Description: … Upon administration, sonepcizumab binds S1P, which may result in the inhibition of tumor angiogenesis …
NGN-401 is a recombinant serotype 9 adeno-associated virus (AAV) encoding an intron encoding a miRNA generating sequence, complementary miRNA binding sites and a full-length human methyl cytosine binding protein 2 (MECP2). Developed by Neurogene Inc., it is being investigated for the treatment of Rett syndrome.
Investigational
Matched Description: … ., it is being investigated for the treatment of Rett syndrome. …
EpiCept NP-1 is a prescription topical analgesic cream designed to provide effective, long-term relief from the pain of peripheral neuropathies. Peripheral neuropathies are medical conditions caused by damage to the nerves in the peripheral nervous system. The peripheral nervous system includes nerves that run from the brain and spinal cord...
Investigational
Matched Description: … prescription topical analgesic cream designed to provide effective, long-term relief from the pain of ... The peripheral nervous system includes nerves that run from the brain and spinal cord to the rest of
XP12B is being developed by Xanodyne Pharmaceuticals for the treatment of menorrhagia (heavy menstrual bleeding). It was granted Fast Track status for this indication by the FDA in November 2004.
Investigational
Matched Description: … XP12B is being developed by Xanodyne Pharmaceuticals for the treatment of menorrhagia (heavy menstrual …
SR-123781A is a synthetic hexadecasaccharide Factor IIa and Xa antagonist. It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).
Investigational
Matched Description: … It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary …
EVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being developed as a treatment for insomnia. It is being developed by Evotec Inc.
Investigational
Matched Description: … EVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being …
S-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.
Investigational
Matched Description: … S-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and …
Methyl undecenoyl leucinate is an active ingredient in whitening creams. It is an α-MSH antagonist that inhibits melanin synthesis and tyrosinase activity and reduces expression of various melanogenic genes.
Experimental
Matched Description: … an α-MSH antagonist that inhibits melanin synthesis and tyrosinase activity and reduces expression of
Displaying drugs 7551 - 7575 of 8033 in total